Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy, if required. ITCA 650 is an investigational new drug and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, has been approved in the U.S., Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Type 2 DiabetesAccording to the National Institutes of Health (NIH), "Approximately 23.6 million Americans have type 2 diabetes, which represents 7.8 percent of the U.S. population and about 1/4 of them don't even know it.  In addition, we now know that at least another 57 million Americans have 'pre-diabetes.'" Diabetes is conservatively estimated to be the seventh leading cause of death in the U.S.  Minority populations are disproportionately affected, particularly African Americans and Hispanics. For example, African Americans are 1.8 times more likely to develop type 2 diabetes compared to non-Hispanic whites.

According to the Centers for Disease Control and Prevention (CDC), the rate of new cases of type 2 diabetes has nearly doubled in the U.S. in the last decade with these new cases mirroring an increase in obesity rates - a leading cause of type 2 diabetes.

About IntarciaIntarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pur
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... addition of Kent Hance , the former chancellor of ... Hance retired as chancellor in July 2014, after raising $1.2 ... announce that Kent Hance , the most successful chancellor ... Kiromic team not only as an investor, but also as ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... Sept. 19, 2014  4WEB Medical announces the formal ... and ankle osteotomy implants on the market today ... annual meeting in Chicago .  The ... a surgeon,s osteotomy needs with 74 size options included in ... offerings of only 15 to 18 implant sizes, which ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the Deutsche Bank 36th Annual ... presentation takes place on Wednesday, May 4, 2011 at 10:40 ... will be webcast and may be accessed on the Company,s ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 ... and chief financial officer at Amylin Pharmaceuticals, will provide a ... through the "Investors" section of Amylin,s corporate website at ...
Cached Medicine Technology:
(Date:9/19/2014)... (PRWEB) September 19, 2014 “Copay coupons,” ... sales of brand drugs among patients with prescription drug ... according to a new report from the Department ... General (OIG). Federal anti-kickback laws prohibit suppliers from offering ... by the federal government. , The report highlights that ...
(Date:9/19/2014)... 2014 BearCom, a nationwide provider ... the key role played by instant, one-to-one and ... healthcare industry. , “In healthcare, speed of ... and in emergency situations, can save precious seconds ... death,” said Hugh Johnston, Product & Purchasing Manager ...
(Date:9/19/2014)... More than half of human cancers have ... yet how these signals are controlled during tumor ... PhD, MD, and Svetlana Fayngerts, PhD, both researchers ... at the Perelman School of Medicine, University of ... described oncogenic protein, promotes cancer by targeting these ...
(Date:9/19/2014)... 19, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care and community-based care, ... Opening Bell yesterday at the New York Stock Exchange. ... and social entrepreneur to care for immigrant families suffering ... always worked to meet the urgent healthcare needs of ...
(Date:9/19/2014)... U.S. military troops deployed to sunny climates may have ... new study. Many returning troops reported getting ... military personnel developed blisters on their skin or noticed ... their moles since being deployed overseas. All of ... the study authors noted. "The past decade of ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:New cancer drug target involving lipid chemical messengers 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2
... endoscopy is a well accepted tool for evaluation of ... some limitations due to restricted recording time and reduced ... preparation (e.g., prokinetic drugs, laxatives and defoaming agents) have ... However, to date no standardized protocol has been recommended ...
... with pancreatico-biliary carcinoma has been reported as a definite ... This study, performed by a team led by Professor ... in a research article to be published on April ... , The study evaluated 31 patients who underwent paraaortic ...
... SAN ANTONIO, May 20 Medco Health Solutions,Inc. ... benefit manager, and,Healthways (Nasdaq: HWAY ), the ... announced the opening of an innovative new,center that ... managing health risks and chronic conditions. The Medco ...
... Recognized Nationally-, WASHINGTON, May 20 Michelle Mays, ... Advocate of the Year,by the Campaign for Tobacco-Free Kids ... being honored at a gala in the nation,s,capital on ... winner,three other regional winners and a group winner., ...
... in the Water Just Like ... BioLab ... marketing communications agency, Fletcher Martin (, http://www.fletchermartin.com ) launched an interactive ... http://www.biolabuv.com ). The,banner-ad game is designed to entice consumers to ...
... available in Spanish . , , A research team from ... on the psychological process that triggers the craving or intense desire ... the brain mechanisms that activate this state and how to control ... Department of Personality, Evaluation and Psychological Treatment of the ...
Cached Medicine News:Health News:How does sodium phosphate combined with bisacodyl affect small intestine? 2Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 2Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 3Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 4Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 5Health News:Campaign for Tobacco-Free Kids Honors Michelle Mays of Rhinelander, WI As Youth Advocate of the Year 2Health News:Fletcher Martin Creates Interactive Game-Ad for BioLab(R) UV for BioGuard(R) 2Health News:A research on 'craving' for tobacco establishes the bases for addiction control 2
ROB-NEL Catheters (100% Latex-Free)...
Red Rubber Robinson Catheters (Latex)...
Urethral Red Rubber Catheters (Latex)...
Foley Catheters (Latex) 3-Way...
Medicine Products: